A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.

Vinfunine (VFL) is a novel bifluorinated tubulin-targeted agent of the vinca alkaloids class active in advanced stage breast cancer. We conducted a phase I study combining VFL with doxorubicin (DXR) to define the recommended dose (RD), safety, pharmacokinetic (PK) interaction and efficacy. Two schedules (day 1 every 3 weeks; days 1 and 8 every 3 weeks) were investigated as first line chemotherapy in metastatic breast cancer patients. Thirty-two patients received a total of 162 cycles of the VFL-DXR combination (median 6). The RDs were VFL 250 mg/m(2)/DXR 40 mg/m(2) every 3 weeks for schedule 1 and VFL 120 mg/m(2)/DXR 25 mg/m(2) days 1 and 8 every 3 weeks for schedule 2. The main dose-limiting toxicity was neutropenia. The most frequent non-hematological adverse events were nausea, fatigue, constipation, vomiting, anorexia, stomatitis and dyspnea. Objective response rate was reached in 47.1% of the patients. No PK interaction was observed. VFL-DXR combination is feasible with manageable toxicity. The antitumor activity was promising and supports further evaluation.

L'hypnose: une ressource en soins palliatifs? Etude qualitative sur l'apport de l'hypnose chez des patients oncologique.s [Hypnosis as a resource in palliative care. A qualitative study of the contribution of hypnosis to the care of oncology patients].

Hypnosis is recognised in medicine as an effective complementary therapy. However, few qualitative data are available concerning the benefits it may bring. This qualitative exploratory study aimed to examine the contribution of hypnosis to the care of advanced cancer patients. Results demonstrate that hypnosis is an effective and efficient means of developing the resources of people suffering from serious illness. After an average of four hypnotherapy sessions, patients said they were able to locate previously unexploited resources within themselves and were able to become autonomous in the use of self-hypnosis. The major benefit reported concerned a reduction in anxiety. For patients experiencing anxiety about death, hypnosis allowed them, within a therapeutic environment perceived as safe, to explore different facets of their fears and to develop adaptive strategies. Aside from slight fatigue experienced during the sessions, no adverse side-effects were reported. In conclusion, this study exploring the effects of hypnosis allowed us to identify important benefits for patients suffering from advanced cancer. Consequently, replication on a larger scale is recommended in order to ascertain the extent to which it is possible to generalise from these results and in order better to define the characteristics of patients most likely to benefit from this therapy.

Alteration in neuromuscular function after a 5 km running time trial

The aim of this study was to characterize the effect of a 5 km running time trial on the neuromuscular properties of the plantar flexors. Eleven well-trained triathletes performed a series of neuromuscular tests before and immediately after the run on a 200 m indoor track. Muscle activation (twitch interpolation) and normalized EMG activity were assessed during maximal voluntary contraction (MVC) of plantar flexors. Maximal soleus H-reflexes and M-waves were evoked at rest (i.e. H (MAX) and M (MAX), respectively) and during MVC (i.e. H (SUP) and M (SUP), respectively). MVC significantly declined (-27%; P < 0.001) after the run, due to decrease in muscle activation (-8%; P < 0.05) and M (MAX)-normalized EMG activity (-13%; P < 0.05). Significant reductions in M-wave amplitudes (M (MAX): -13% and M (SUP): -16%; P < 0.05) as well as H (MAX)/M (MAX) (-37%; P < 0.01) and H (SUP)/M (SUP) (-25%; P < 0.05) ratios occurred with fatigue. Following exercise, the single twitch was characterized by lower peak torque (-16%; P < 0.001) as well as shorter contraction (-19%; P < 0.001) and half-relaxation (-24%; P < 0.001) times. In conclusion, the reduction in plantar flexors strength induced by a 5 km running time trial is caused by peripheral adjustments, which are attributable to a failure of the neuromuscular transmission and excitation-contraction coupling. Fatigue also decreased the magnitude of efferent motor outflow from spinal motor neurons to the plantar flexors and part of this suboptimal neural drive is the result of an inhibition of soleus motoneuron pool reflex excitability.

Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women - PREFER a Randomized, Placebo-Controlled Study

BACKGROUND: Unexplained fatigue is often left untreated or treated with antidepressants. This randomized, placebo-controlled, single-blinded study evaluated the efficacy and tolerability of single-dose intravenous ferric carboxymaltose (FCM) in iron-deficient, premenopausal women with symptomatic, unexplained fatigue. METHODS: Fatigued women (Piper Fatigue Scale [PFS] score ≥5) with iron deficiency (ferritin <50 µg/L and transferrin saturation <20%, or ferritin <15 µg/L) and normal or borderline hemoglobin (≥115 g/L) were enrolled in 21 sites in Austria, Germany, Sweden and Switzerland, blinded to the study drug and randomized (computer-generated randomization sequence) to a single FCM (1000 mg iron) or saline (placebo) infusion. Primary endpoint was the proportion of patients with reduced fatigue (≥1 point decrease in PFS score from baseline to Day 56). RESULTS: The full analysis included 290 women (FCM 144, placebo 146). Fatigue was reduced in 65.3% (FCM) and 52.7% (placebo) of patients (OR 1.68, 95%CI 1.05-2.70; p = 0.03). A 50% reduction of PFS score was achieved in 33.3% FCM- vs. 16.4% placebo-treated patients (p<0.001). At Day 56, all FCM-treated patients had hemoglobin levels ≥120 g/L (vs. 87% at baseline); with placebo, the proportion decreased from 86% to 81%. Mental quality-of-life (SF-12) and the cognitive function scores improved better with FCM. 'Power of attention' improved better in FCM-treated patients with ferritin <15 µg/L. Treatment-emergent adverse events (placebo 114, FCM 209; most frequently headache, nasopharyngitis, pyrexia and nausea) were mainly mild or moderate. CONCLUSION: A single infusion of FCM improved fatigue, mental quality-of-life, cognitive function and erythropoiesis in iron-deficient women with normal or borderline hemoglobin. Although more side effects were reported compared to placebo, FCM can be an effective alternative in patients who cannot tolerate or use oral iron, the common treatment of iron deficiency. Overall, the results support the hypothesis that iron deficiency can affect women's health, and a normal iron status should be maintained independent of hemoglobin levels. TRIAL REGISTRATION: ClinicalTrials.gov NCT01110356.

Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.

Pancreatic neuroendocrine tumors (pNETs) are infrequent malignancies which manifest in both functional (hormone-secreting) and more commonly non-functional (non-secreting) forms. The oral multitargeted tyrosine kinase inhibitor sunitinib and mammalian target of rapamycin (mTOR) inhibitor everolimus are approved as targeted therapies for patients with well-differentiated, non-resectable disease and evidence of disease progression. The recent approval of sunitinib for the management of advanced pNET is based on a continuous daily dosing (CDD) schedule that differs from the intermittent 4weeks on/2weeks off (4/2) schedule approved for sunitinib in advanced renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Therefore, although clinicians may be familiar with therapy management approaches for sunitinib in advanced RCC and GIST, there is less available experience for the management of patients with a CDD schedule. Here, we discuss the similarities and differences in the treatment of pNET with sunitinib compared with advanced RCC and GIST. In particular, we focus on the occurrence and management of sunitinib-related toxicity in patients with pNET by drawing on experience in these other malignancies. We aim to provide a relevant and useful guide for clinicians treating patients with pNET covering the management of events such as fatigue, mucositis, hand-foot syndrome, and hypertension.

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma

Introduction: Mantle cell lymphoma (MCL) accounts for 6% of all B-cell lymphomas and remains incurable for most patients. Those who relapse after first line therapy or hematopoietic stem cell transplantation have a dismal prognosis with short response duration after salvage therapy. On a molecular level, MCL is characterised by the translocation t[11;14] leading to Cyclin D1 overexpression. Cyclin D1 is downstream of the mammalian target of rapamycin (mTOR) kinase and can be effectively blocked by mTOR inhibitors such as temsirolimus. We set out to define the single agent activity of the orally available mTOR inhibitor everolimus (RAD001) in a prospective, multi-centre trial in patients with relapsed or refractory MCL (NCT00516412). The study was performed in collaboration with the EU-MCL network. Methods: Eligible patients with histologically/cytologically confirmed relapsed (not more than 3 prior lines of systemic treatment) or refractory MCL received everolimus 10 mg orally daily on day 1 - 28 of each cycle (4 weeks) for 6 cycles or until disease progression. The primary endpoint was the best objective response with adverse reactions, time to progression (TTP), time to treatment failure, response duration and molecular response as secondary endpoints. A response rate of 10% was considered uninteresting and, conversely, promising if 30%. The required sample size was 35 pts using the Simon's optimal two-stage design with 90% power and 5% significance. Results: A total of 36 patients with 35 evaluable patients from 19 centers were enrolled between August 2007 and January 2010. The median age was 69.4 years (range 40.1 to 84.9 years), with 22 males and 13 females. Thirty patients presented with relapsed and 5 with refractory MCL with a median of two prior therapies. Treatment was generally well tolerated with anemia (11%), thrombocytopenia (11%), neutropenia (8%), diarrhea (3%) and fatigue (3%) being the most frequent complications of CTC grade III or higher. Eighteen patients received 6 or more cycles of everolimus treatment. The objective response rate was 20% (95% CI: 8-37%) with 2 CR, 5 PR, 17 SD, and 11 PD. At a median follow-up of 6 months, TTP was 5.45 months (95% CI: 2.8-8.2 months) for the entire population and 10.6 months for the 18 patients receiving 6 or more cycles of treatment. Conclusion: This study demonstrates that single agent everolimus 10 mg once daily orally is well tolerated. The null hypothesis of inactivity could be rejected indicating a moderate anti-lymphoma activity in relapsed/refractory MCL. Further studies of either everolimus in combination with chemotherapy or as single agent for maintenance treatment are warranted in MCL.

Health at work and risk factors related to ergonomics: some results from the Swiss sample of the 4th European working conditions survey

Introduction The European Foundation for the improvement of living and working conditions conducts a survey every 5 years since 1990. The foundation also offers the possibility to non-EU countries to be included in the survey: in 2005, Switzerland took part for the first time in the fourth edition of this survey. The Institute for Work and Health (IST) has been associated to the Swiss project conducted under the leadership of the SECO and the Fachhochschule Nordwestschweiz. The survey covers different aspects of work like job characteristics and employment conditions, health and safety, work organization, learning and development opportunities, and the balance between working and non-working life (Parent-Thirion, Fernandez Macias, Hurley, & Vermeylen, 2007). More particularly, one question assesses the worker's self-perception of the effects of work on health. We identified (for the Swiss sample) several factors affecting the risk to report health problems caused by work. The Swiss sample includes 1040 respondents. Selection of participants was based on a random multi-stage sampling and was carried out by M.I.S Trend S.A. (Lausanne). Participation rate was 59%. The database was weighted by household size, gender, age, region of domicile, occupational group, and economic sector. Specially trained interviewers carried out the interviews at the respondents home. The survey was carriedout between the 19th of September 2005 and the 30th of November 2005. As detailed in (Graf et al., 2007), 31% of the Swiss respondents identify work as the cause of health problems they experience. Most frequently reported health problems include back pain (18%), stress (17%), muscle pain (13%), and overall fatigue (11%). Ergonomic aspects associated with higher risk of reporting health problems caused by work include frequent awkward postures (odds ratio [OR] 4.7, 95% confidence interval [CI] 3.1 to 5.4), tasks involving lifting heavy loads (OR 2.7, 95% CI 2.0 to 3.6) or lifting people (OR 2.2, 95% CI 1.4 to 3.5), standing or walking (OR 1.4, 95% CI 1.1 to 1.9), as well as repetitive movements (OR 1.7, 95% CI 1.3 to 2.3). These results highlight the need to continue and intensify the prevention of work related health problems in occupations characterized by risk factors related to ergonomics.

RTOG 0525: A randomized phase iii trial comparing standard adjuvant temozolomide (tmz) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (gbm)

Radiotherapy with concomitant and adjuvant TMZ is the standard of care for newly diagnosed GBM. MGMT methylation status may be an important determinant of treatment response. This trial, conducted by the RTOG, EORTC, and NCCTG, determined if intensified TMZ improves survival (OS) or progression free survival (PFS) in all patients or specific to MGMT status. Eligibility criteria included age . 18 yrs, KPS ≥ 60, and existence of a tissue block with . 1cm2 tumor for prospective MGMT and retrospective molecular analysis. Patients were randomized to Arm 1: standard TMZ (150-200 mg/m2 x 5 d) or Arm 2: dd TMZ (75-100 mg/m2 x 21 d) q 4 wks for 6-12 cycles. Symptom burden, quality of life (QOL), and neurocognition were prospectively and longitudinally assessed in a patient subset. 833 patients were randomized (1173 registered). Inadequate tissue (n ¼ 144) was the most frequent reason for nonrandomization.No statistical difference was observed between Arms 1 and 2 for median OS (16.6, 14.9 mo, p ¼ 0.63), median PFS (5.5, 6.7 mo, p ¼ 0.06), or methylation status. MGMT methylation was associated with improved OS (21.2, 14 mo, p , 0.0001), PFS (8.7, 5.7 mo, p , 0.0001), and treatment response (p ¼ 0.012). Cox modeling identifiedMGMT status and RPA class as significant predictors of OS; treatment arm and radiation technique (EORTC vs. RTOG) were not. There was increased grade ≥ 3 toxicity in Arm 2 (19%, 27%, p ¼ 0.008), which was mostly lymphopenia and fatigue. This study did not demonstrate improved efficacy for dd TMZ for newly diagnosed GBM regardless of methylation status. However, it confirmed the prognostic significance of MGMT methylation in GBM, demonstrated the feasibility of tumor tissue collection, molecular stratification, and collection of patient outcomes in a large transatlantic intergroup trial, thereby establishing a viable clinical trial paradigm. Support: NCI U10 CA 21661 and U10 CA37422.

A new paradigm of neuromuscular electrical stimulation for the quadriceps femoris muscle.

PURPOSE: Neuromuscular electrical stimulation (NMES) with large electrodes and multiple current pathways (m-NMES) has recently been proposed as a valid alternative to conventional NMES (c-NMES) for quadriceps muscle (re)training. The main aim of this study was to compare discomfort, evoked force and fatigue between m-NMES and c-NMES of the quadriceps femoris muscle in healthy subjects. METHODS: Ten healthy subjects completed two experimental sessions (c-NMES and m-NMES), that were randomly presented in a cross-over design. Maximal electrically evoked force at pain threshold, self-reported discomfort at different levels of evoked force, and fatigue-induced force declines during and following a series of 20 NMES contractions were compared between c-NMES and m-NMES. RESULTS: m-NMES resulted in greater evoked force (P < 0.05) and lower discomfort in comparison to c-NMES (P < 0.05-0.001), but fatigue time course and magnitude did not differ between the two conditions. CONCLUSIONS: The use of quadriceps m-NMES appears legitimate for (re)training purposes because it generated stronger contractions and was less discomfortable than c-NMES (due to multiple current pathways and/or lower current density with larger electrodes).

Le réentraînement à l'effort chez l'enfant atteint de paralysie cérébrale (PC)

Le réentraînement à l'effort est présenté aujourd'hui comme un moyen efficace de lutter et réduire des déficiences chroniques chez l'adulte atteint de pathologie chronique. Il a été proposé plus récemment chez le jeune (enfant ou adolescent) atteint de pathologies neurologiques, notamment la paralysie cérébrale. De nombreuses études à ce jour présentent des résultats encourageants dans l'amélioration de certains facteurs de qualité de vie chez des jeunes patients atteints de paralysie cérébrale. Tout d'abord, un entraînement à l'effort sur la base d'exercices réalisés en endurance permet d'améliorer les capacités aérobies ainsi que le périmètre et la vitesse de marche et la motricité globale. Un entraînement à base de renforcement musculaire favoriserait aussi l'augmentation de la masse musculaire et induirait une amélioration de la motricité globale. Enfin, il semble que le type d'exercice à privilégier actuellement soit un entraînement « mixte », à base d'exercices associant les deux modes d'entraînement précédents. Pour préciser les modalités pratiques de réalisation de ces entraînements, il faudra tenir compte de différents paramètres parmi lesquels la fatigue musculaire.

Physiological differences between cycling and running

This review compares the differences in systemic responses (VO2max, anaerobic threshold, heart rate and economy) and in underlying mechanisms of adaptation (ventilatory and hemodynamic and neuromuscular responses) between cycling and running. VO2max is specific to the exercise modality. Overall, there is more physiological training transfer from running to cycling than vice-versa. Several other physiological differences between cycling and running are discussed: HR is different between the two activities both for maximal and sub-maximal intensities. The delta efficiency is higher in running. Ventilation is more impaired in cycling than running due to mechanical constraints. Central fatigue and decrease in maximal strength are more important after prolonged exercise in running than in cycling.

Pour une histoire croisée des dispositifs audiovisuels et des sciences du psychisme autour de 1900 : la construction du spectateur cinématographique

Réalisée dans le cadre du projet de recherche initié à la section d'histoire et esthétique du cinéma de l'Université de Lausanne autour du concept « d'Épistémè 1900 », cette thèse cherche à mettre en rapport dialogique deux « ensembles » formés par l'histoire du cinéma et l'histoire des sciences du psychisme dans une période circonscrite entre 1880 et 1910. Il s'agit de repenser les liens entre cinéma et sciences du psychisme, chacun de ces ensembles discursifs étant traités au même niveau en tant qu'objets historiques de savoir qui ont des choses à nous apprendre sur le cinéma en tant que phénomène culturel, anthropologique et social. Au passage du siècle, cinéma et sciences du psychisme se rencontrent au coeur d'une nouvelle problématisation du sujet définie par des savoirs scientifiques et parascientifiques alors confrontés aux phénomènes intriguants de l'hystérie et de l'hypnose. L'hystérie et l'hypnose provoquent des états nerveux lesquels constituent un terrain propice au développement de sujets divisés, hallucinés et intrancés, conduisant les médecins et psychologues à remettre en question l'idée d'un moi homogène et contrôlé. L'expansion d'une culture névrotique fabriquant à la chaîne des corps automatiques voués à leur inconscient cérébral permet de rapprocher le cinéma et les théories du psychisme sur une base qui a été rarement explorée jusqu'ici, en particulier relativement à la construction (théorique) du spectateur de cinéma. Si le dispositif cinématographique en tant que technique, représentation et modèle de pensée reprend à son compte l'imaginaire médical de cette époque, il contribue également en retour à façonner une conception de la subjectivité étroitement tributaire des technologies contemporaines et des fantasmes qu'elles génèrent. Aux côtés des personnages hystériques filmés par les premiers opérateurs, les spectateurs tels que décrits dans les textes-sources participent, d'une part à attester de la persistance du modèle neuro-pathologique dans la culture visuelle du début du XXe siècle, et d'autre part à transformer la vision savante du sujet dans ses rapports perceptifs et affectifs avec le monde environnant. C'est donc dans une logique d'interactions réciproques qu'il faut envisager les rapports entre le cinéma (conçu ici essentiellement comme comme un dispositif réunissant un appareillage, une image et un spectateur) et les connaissances relatives à l'intériorité psychique qui s'élaborent dans le domaine des sciences médico-psychologiques. Pour étudier ces rapports, j'ai choisi la figure du spectateur puisque les théories du psychisme s'intéressent prioritairement à l'humain et à sa subjectivité. À partir de cette figure-clé, j'ai tenté de montrer comment le spectacle cinématographique et les sciences du psychisme participent à des réflexions sur l'avènement d'une nouvelle forme de subjectivité consonante avec la modernité, une modernité qui bouleverse la manière d'envisager le fonctionnement de l'appareil psychique, donc les rapports de l'individu à soi-même et à ses images, mais aussi aux autres et au monde en général. Les croisements entre le sujet du cinéma et le sujet des sciences du psychisme s'effectuent autour de quatre paradigmes selon moi définitoires de la subjectivité autour de 1900 et structurant l'ensemble de cette recherche : la fatigue, le choc, l'hallucination et l'hypnose. En parcourant les sources, on s'aperçoit en effet qu'elles envisagent le corps humain tantôt comme une machine (un corps thermodynamique et électrophysiologique), tantôt comme hystérique ou neurasthénique (un corps traumatique et dysfonctionnel), tantôt comme rêveur (un corps producteur d'images et de sons perçus sur un mode hallucinatoire), tantôt comme hypermnésique (un corps de « clichés-souvenirs » emmagasinés à l'infini), tantôt comme hypnotisé (un corps suggestionné et contagieux). Tous ces corps, au final, ne forment qu'un seul corps générique, c'est-à-dire construisent et qualifient le corps nerveux des sciences du psychisme qui se manifeste sous différentes facettes en fonction des pathologies et des situations. À la fois unique et multiple, ce corps nerveux subsume le corpsmachine, le corps traumatisé, le corps halluciné et le corps hypnotisé qui font l'objet d'analyse détaillées dans les différentes parties de la thèse. Ces quatre grands « corps » retenus comme autant de déclinaisons possibles du corps nerveux sont directement mis en rapport avec quatre concepts : la fatigue, le choc, l'hallucination et l'hypnose - ce choix s'imposant face au constat de leur récurrence suite au dépouillement de nombreuses sources. J'ai tenté, au cours de ce travail, de défendre plusieurs hypothèses (ou séries d'hypothèses) relatives à l'avènement du spectateur cinématographique autour de 1900. Corrélées les unes aux autres, elles gagnent à être comprises ensemble. 1) Les sciences du psychisme et les discours sur les spectacles et dispositifs audiovisuels contribuent, dans leurs échanges, à la construction du sujet moderne, un sujet né de la révolution industrielle et s'épanouissant grâce à la culture de masse. La culture de masse met en scène des corps nerveux (automatiques, traumatisés, hallucinés et hypnotisés) dont la démultiplication sous différentes formes et en différents lieux fait émerger un nouveau modèle de subjectivité. Si le cinéma constitue un laboratoire expérimental du corps nerveux, il participe également à la transformation du corps nerveux en sujet nerveux, c'est-à-dire en un sujet moderne jouissant d'un nervosisme mué en modèle culturel. 2) Le cinématographe devient autour de 1900 un dispositif modélisateur pour les sciences du psychisme qui conceptualisent le fonctionnement de l'appareil psychique sous les espèces d'une machine projetant des sons et des images. En tant qu'opérateur de pensée, le cinéma offre une pluralité de modèles épistémologiques possibles, suivant que l'on s'intéresse à son fonctionnement général, ses détails techniques, ses effets sur les spectateurs, sa dimension spectaculaire et populaire. Par conséquent, le cinéma peut étayer une variété d'objets dans le champ des sciences médicales : le corps, l'esprit, la pensée, l'imagination, le rêve, l'hallucination, l'hypnose, la psychose ; mais aussi le corps individuel ou social, qu'ils soient sains ou malades. C'est sur cette base, j'en viens à penser que le spectateur de cinéma sert de modèle au sujet nerveux des sciences médicales. 3) Le rôle modélisateur du cinéma provoque en effet des modifications dans la manière de théoriser le corps nerveux puisqu'il fait transiter le corps nerveux de la psychopathologie vers le sujet nerveux de la culture spectaculaire moderne. Le spectateur du cinéma des premiers temps apparaît comme le prototype du sujet sidéré par le spectacle du monde moderne, prenant plaisir à être surstimulé et se prêtant volontiers au jeu de l'illusion de réalité. Actualisant un modèle de spectatorialité ambivalent, balançant entre hystérie et hypnose, le spectateur cinématographique intègre les codes de la maladie nerveuse pour leur donner une nouvelle dimension (esthétique, artistique) sur la scène sociale. 4) Les trois premières séries d'hypothèses ne peuvent être validées que si l'on examine comment les discours sur le cinéma pré-institutionnel se sont appropriés la culture du corps nerveux, de sorte à façonner un modèle de spectatorialité étayé sur les valeurs féminines d'impressionnabilité, d'excitabilité et de sentimentalité (des valeurs culturellement construites). Partant, j'ai voulu montrer que si durant la première phase de son histoire, le spectacle cinématographique fait l'objet d'une hystéricisation de la part des discours qui l'annexent à la sphère féminine de la culture de masse, dans sa phase d'institutionnalisation, on assiste à un processus de masculinisation du modèle spectatoriel (mais également, des lieux d'exibition, du mode de production, du mode de représentation, etc.).

The Lausanne cohort Lc65+: a population-based prospective study of the manifestations, determinants and outcomes of frailty

BACKGROUND: Frailty is a relatively new geriatric concept referring to an increased vulnerability to stressors. Various definitions have been proposed, as well as a range of multidimensional instruments for its measurement. More recently, a frailty phenotype that predicts a range of adverse outcomes has been described. Understanding frailty is a particular challenge both from a clinical and a public health perspective because it may be a reversible precursor of functional dependence. The Lausanne cohort Lc65+ is a longitudinal study specifically designed to investigate the manifestations of frailty from its first signs in the youngest old, identify medical and psychosocial determinants, and describe its evolution and related outcomes. METHODS/DESIGN: The Lc65+ cohort was launched in 2004 with the random selection of 3054 eligible individuals aged 65 to 70 (birth year 1934-1938) in the non-institutionalized population of Lausanne (Switzerland). The baseline data collection was completed among 1422 participants in 2004-2005 through questionnaires, examination and performance tests. It comprised a wide range of medical and psychosocial dimensions, including a life course history of adverse events. Outcomes measures comprise subjective health, limitations in activities of daily living, mobility impairments, development of medical conditions or chronic health problems, falls, institutionalization, health services utilization, and death. Two additional random samples of 65-70 years old subjects will be surveyed in 2009 (birth year 1939-1943) and in 2014 (birth year 1944-1948). DISCUSSION: The Lc65+ study focuses on the sequence "Determinants --> Components --> Consequences" of frailty. It currently provides information on health in the youngest old and will allow comparisons to be made between the profiles of aging individuals born before, during and at the end of the Second World War.

One case, 3 rare simultaneous findings: intramyocardial bronchogenic cyst, P.H558R variant of SCN5A gene, and granular cell tumor of the esophagus.

We describe the sudden death of a 42-year-old white man. The decedent was a healthy young man with a short clinical history of chest pain, fatigue, dizziness, and pyrosis. Two weeks before his death, he underwent medical evaluation for the aforementioned symptoms. Electrocardiogram, chest x-ray, and serum troponin were all within normal limits. Gastroesophageal reflux disease was suspected, and the decedent was treated with omeprazole. Medicolegal autopsy disclosed an incidental intramyocardial bronchogenic cyst and p.H558R variant of the SCN5A gene. The cyst was located between the epicardium and myocardium of the posterior face of the left superior ventricular wall, adjacent to the base of the heart. An incidental granular cell tumor of the esophagus was also identified, which was likely unrelated to death.

Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society

In this study of the efficacy and safety of isradipine as first-line therapy in hypertension, 1,647 patients enrolled; 1,472 completed the 4-week placebo run-in period and began treatment with isradipine at 2.5 mg twice daily for 4 weeks. During placebo, 11% (n = 175) of the 1,647 patients withdrew because of normalization of blood pressure, side effects, noncompliance, violation of the study protocol, side effects from concomitant therapy, or other reasons. During isradipine therapy (n = 1,376), blood pressure decreased from 168 +/- 18/102 +/- 8 mm Hg at the end of the placebo period to 155 +/- 17/94 +/- 9 mm Hg after 2 weeks (p less than 0.001) and 151 +/- 16/92 +/- 9 mm Hg after 4 weeks (p less than 0.001). During active treatment, 6.4% (n = 94) were withdrawn because of flushing, headache, edema, palpitations, gastrointestinal side effects, skin rashes, or other side effects, and two patients because of lack of efficacy. The side effect score in the remaining patients worsened for flushing, remained unchanged for edema, but significantly improved for palpitations, fatigue, dizziness, headache, and nervousness. After 4 weeks, 60% of patients had diastolic blood pressures of less than or equal to 90 mm Hg. Thus, isradipine is effective and safe as first-line therapy in patients with primary hypertension as seen in general practice.